Skip to main content
SpringerLink
Log in

Lung Cancer

  • Chapter
  • First Online:
Target Volume Delineation and Treatment Planning for Particle Therapy

Part of the book series: Practical Guides in Radiation Oncology ((PGRO))

  • 1628 Accesses

Abstract

Lung cancer is one of the most common malignancies, accounting for approximately 225,000 new cases and 160,000 deaths per year [1]. Treatment of lung cancer is dependent on stage, with early stages treated by surgery or radiation alone and more advanced tumors receiving bi- or trimodality therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Larsen H, Sorensen JB, Nielsen AL, Dombernowsky P, Hansen HH. Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable non-small-cell lung cancer (NSCLC). Ann Oncol. 1995;6(10):993–7.

    Article  CAS  PubMed  Google Scholar 

  2. Zhang X, Li Y, Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol biol Phys. 2010;77(2):357–66.

    Article  PubMed  Google Scholar 

  3. Wang C, Nakayama H, Sugahara S, Sakae T, Tokuuye K. Comparisons of dose-volume histograms for proton-beam versus 3-D conformal x-ray therapy in patients with stage I non-small cell lung cancer. Strahlenther Onkol. 2009;185(4):231–4.

    Article  PubMed  Google Scholar 

  4. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol biol Phys. 2006;65(4):1087–96.

    Article  PubMed  Google Scholar 

  5. Nguyen QN, Ly NB, Komaki R, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II–III inoperable non-small cell lung cancer. Radiother Oncol. 2015;115(3):367–72.

    Article  PubMed  PubMed Central  Google Scholar 

  6. McAvoy SA, Ciura KT, Rineer JM, et al. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013;109(1):38–44.

    Article  PubMed  Google Scholar 

  7. Ishikawa Y, Nakamura T, Kato T, et al. Dosemetric parameters predictive of rib fractures after proton beam therapy for early-stage lung cancer. Tohoku J Exp Med. 2016;238(4):339–45.

    Article  CAS  PubMed  Google Scholar 

  8. Hoppe BS, Henderson R, Pham D, et al. A phase 2 trial of concurrent chemotherapy and proton therapy for stage III non-small cell lung cancer: results and reflections following early closure of a single-institution study. Int J Radiat Oncol biol Phys. 2016;95(1):517–22.

    Article  PubMed  Google Scholar 

  9. Bush DA, Cheek G, Zaheer S, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University medical Center. Int J Radiat Oncol Biol Phys. 2013;86(5):964–8.

    Article  PubMed  Google Scholar 

  10. Colaco RJ, Huh S, Nichols RC, et al. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer. Acta Oncol. 2013;52(3):506–13.

    Article  PubMed  Google Scholar 

  11. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 2000;48(4):1015–24.

    Article  CAS  PubMed  Google Scholar 

  12. Kelly P, Balter PA, Rebueno N, et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys. 2010;78(5):1387–93.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Chang JY, Roth JA. Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin. 2007;17(2):251–9.

    Article  PubMed  Google Scholar 

  14. Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):967–71.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–71.

    Article  CAS  PubMed  Google Scholar 

  17. Zhang W, Liu C, Lin H, et al. Prospective study of special stage II (T2b-3N0M0) non-small-cell lung cancer treated with hypofractionated-simultaneous integrated boost-intensity modulated radiation therapy. J Cancer Res Ther. 2015;11(2):381–7.

    Article  CAS  PubMed  Google Scholar 

  18. Weiss E, Fatyga M, Wu Y, et al. Dose escalation for locally advanced lung cancer using adaptive radiation therapy with simultaneous integrated volume-adapted boost. Int J Radiat Oncol Biol Phys. 2013;86(3):414–9.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ji K, Zhao LJ, Liu WS, et al. Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study. Br J Radiol. 2014;87(1035):20130562.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Dirkx ML, van Sornsen De Koste JR, Senan S. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer. Lung Cancer. 2004;45(1):57–65.

    Article  PubMed  Google Scholar 

  21. Kang Y, Zhang X, Chang JY, et al. 4D proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys. 2007;67(3):906–14.

    Article  PubMed  Google Scholar 

  22. Liu W, Schild SE, Chang JY, et al. Exploratory study of 4D versus 3D robust optimization in intensity modulated proton therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):523–33.

    Article  PubMed  Google Scholar 

  23. Li H, Zhu XR, Zhang X. Reducing dose uncertainty for spot-scanning proton beam therapy of moving Tumors by optimizing the spot delivery sequence. Int J Radiat Oncol Biol Phys. 2015;93(3):547–56.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Li H, Zhang X, Park P, et al. Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiother Oncol. 2015;114(3):367–72.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Chang JY, Li H, Zhu XR, et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014;90(4):809–18.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Bush DA, Slater JD, Bonnet R, et al. Proton-beam radiotherapy for early-stage lung cancer. Chest. 1999;116(5):1313–9.

    Article  CAS  PubMed  Google Scholar 

  27. Chang JY, Komaki R, Wen HY, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;80(5):1350–7.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Do SY, Bush DA, Slater JD. Comorbidity-adjusted survival in early stage lung cancer patients treated with hypofractionated proton therapy. J Oncol. 2010;2010:251208.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Niho S, Motegi A, Kirita K, et al. Proton beam therapy (PBT) and concurrent chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) for locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15):e18525.

    Google Scholar 

  30. Nguyen Q, Komaki R, Liao Z, et al. The 5-year outcome for patients diagnosed with locally advanced non-small cell lung cancer treated with definitive concurrent chemotherapy and proton beam therapy. Int J Radiat Oncol. 2014;90:S19–20.

    Article  Google Scholar 

  31. Lievens Y, Verhaeghe N, de Neve W, et al. Proton radiotherapy for locally-advanced non-small cell lung cancer, a cost-effective alternative to photon radiotherapy in Belgium? J Thorac Oncol. 2013;8:S839–S40.

    Google Scholar 

  32. Koay EJ, Lege D, Mohan R, Komaki R, Cox JD, Chang JY. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1093–100.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kesarwala AH, Ko CJ, Ning H, et al. Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a Dosimetric study. Clin Lung Cancer. 2015;16(3):237–44.

    Article  PubMed  Google Scholar 

  34. Kesarwala AH, Ko C, O'Meara WP, et al. Feasibility of proton therapy for elective nodal irradiation in patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol. 2012;84(3):S577–S8.

    Article  Google Scholar 

  35. Oshiro Y, Mizumoto M, Okumura T, et al. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2012;7(2):370–5.

    Article  PubMed  Google Scholar 

  36. Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011;117(20):4707–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Xiang ZL, Erasmus J, Komaki R, Cox JD, Chang JY. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiat Oncol. 2012;7:144.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Liao ZX, Lee JJ, Komaki R, Gomez DR, O'Reilly M, Allen P, Fossella FV, Heymach JV, Blumenschein GR, Choi NC, Delaney T, Hahn SM, Lu C, Cox JD, Mohan R. Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. J Clin Oncol. 2016;34(suppl):abstr 8500.

    Google Scholar 

  39. Yamada T, Miyamoto N, Matsuura T, et al. Optimization and evaluation of multiple gating beam delivery in a synchrotron-based proton beam scanning system using a real-time imaging technique. Phys Med. 2016;32(7):932–7.

    Article  PubMed  Google Scholar 

  40. Hoffmann L, Alber M, Jensen MF, Holt MI, Moller DS. Adaptation is mandatory for intensity modulated proton therapy of advanced lung cancer to ensure target coverage. Radiother Oncol. 2017;122(3):400–5.

    Article  PubMed  Google Scholar 

  41. Ding X, Li X, Zhang JM, Kabolizadeh P, Stevens C, Yan D. Spot-scanning proton arc (SPArc) therapy: the first robust and delivery-efficient spot-scanning proton arc therapy. Int J Radiat Oncol Biol Phys. 2016;96(5):1107–16.

    Article  PubMed  Google Scholar 

  42. Smith B, Gelover E, Moignier A, et al. Technical note: a treatment plan comparison between dynamic collimation and a fixed aperture during spot scanning proton therapy for brain treatment. Med Phys. 2016;43(8):4693.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA

    Daniel Gomez & Steven Lin

  2. Department of Radiation Physics, MD Anderson Cancer Center, Houston, TX, USA

    Heng Li & Xiaodong Zhang

Authors
  1. Daniel Gomez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaodong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Gomez .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    Nancy Y. Lee

  2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA

    Jonathan E. Leeman

  3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA

    Oren Cahlon

  4. Department of Medical Dosimetry, ProCure Proton Therapy Center, Somerset, New Jersey, USA

    Kevin Sine

  5. Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China

    Guoliang Jiang

  6. Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China

    Jiade J. Lu

  7. Department of Radiation Oncology, University Medical Center Groningen, Groningen, The Netherlands

    Stefan Both

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Gomez, D., Li, H., Zhang, X., Lin, S. (2018). Lung Cancer. In: Lee, N., et al. Target Volume Delineation and Treatment Planning for Particle Therapy. Practical Guides in Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42478-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42478-1_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42477-4

  • Online ISBN: 978-3-319-42478-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation